Analysts are intrested in these 5 stocks: ( ($SRPT) ), ( ($ASTS) ), ( ($CRWV) ), ( ($ENPH) ) and ( ($PSKY) ). Here is a breakdown of their recent ...

Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.

A Cambridge biomedical research institute that launched last year with a roughly $600 million venture capital investment has ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, both dates inclusive (the ...

Discover the challenges and opportunities for Keros Therapeutics, Inc., including FDA designations, partnerships, and ...

Certain Sarepta Therapeutics Inc. insiders were accused in a stockholder lawsuit of reaping a combined $6.2 million selling ...

Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

Here are some of the stories Wall Street is watching on Thursday, Aug. 21. All three of the major indexes (^DJI, ^GSPC, ^IXIC ...

Following recent FDA-related challenges and cost-cutting initiatives, Sarepta has secured an extension on a large chunk of ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.